**LncRNA SNHG14 contributes to the progression of NSCLC through miR-206/G6PD pathway**

Lin Zhao1, Xiaodong Zhang2, Yantong Shi1 & Tianlu Teng3

1 Department of Respiratory Medicine, Affiliated Rizhao People’s Hospital of Jining Medical University, Rizhao, China
2 Department of Clinical Laboratory, Rizhao Center for Disease Control and Prevention, Rizhao, China
3 Department of Respiratory Medicine, Beijing Chest Hospital, Capital Medical University, Beijing, China

Keywords
G6PD; lncRNA SNHG14; miR-206; NSCLC.

**Abstract**

**Background:** Previous studies have shown that the dysregulation of lncRNAs participates in non-small cell lung cancer (NSCLC) development. The purpose of this study was to research the biological function of lncRNA SNHG14 and its molecular mechanism in NSCLC progression.

**Methods:** RT-PCR was applied for investigating the expression of SNHG14, miR-206 and G6PD. The progression of NSCLC was detected by CCK-8, Transwell and western blot assays. The targets of SNHG14 and miR-206 were measured by dual-luciferase reporter assay.

**Results:** We found a higher expression of SNHG14 in NSCLC and upregulation of SNHG14 contributed to NSCLC cell proliferation, invasion and migration. However, knockdown of SNHG14 showed the opposite effect on the progression of NSCLC. Specifically, SNHG14 negatively regulated miR-206 expression by binding with it directly. Furthermore, G6PD served as the target of miR-206. Rescue experiments showed that SNHG14 promoted G6PD expression by inhibiting miR-206.

**Conclusions:** LncRNA SNHG14 contributed to NSCLC progression through miR-206/G6PD axis, providing novel clues for understanding the mechanism of NSCLC.

**Introduction**

Lung cancer is a malignant tumor with the highest morbidity and mortality in China, which seriously threatens the life and health of people. More than 85% of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC). In the past 50 years, the incidence and mortality of lung cancer has been reported to have increased significantly, accounting for the first in all malignant tumors, especially in men. Currently, researchers have spared no efforts to explore the pathogenesis of lung cancer in order to apply it to clinical treatment as soon as possible. However, effective interventions and procedures for NSCLC have so far been rare. Therefore, searching for new therapeutic targets is very important.

LncRNAs have been reported to participate in the progression of various types of tumors, including lung cancer. For example, Yu et al. found that lncRNA FBXL19-AS1 was highly expressed in NSCLC and its high expression enhanced cell proliferation and metastasis. Zheng and colleagues revealed that lncRNA HOXA-AS2 played a facilitating role in NSCLC metastasis. The role of lncRNA NORAD in NSCLC was discovered by Chen et al. in promoting the development of lung cancer. However, the role of lncRNA SNHG14 in lung cancer remains unclear. LncRNA SNHG14, alternatively named UBE3AATS, has been reported to be involved in the development of tumors, including ovarian cancer, bladder and cervical cancer.

Here, we explored the role of lncRNA SNHG14 in NSCLC progression, and investigated whether SNHG14 was expressed abnormally in NSCLC. Moreover, SNHG14 expression was increased or decreased in NSCLC cells to investigate the biological function of SNHG14 in NSCLC cell proliferation, invasion and migration. Additionally, a previous study showed that SNHG14 promoted cervical cancer progression by regulating miR-206, and Cui et al. found that miR-206...
hindered cervical cancer cell proliferation by targeting G6PD. Thus, in our study, we explored whether SNHG14 could modulate miR-206/G6PD axis to better understand the mechanism of SNHG14 in the regulation of the progression of NSCLC.

Here, we investigated both the functional role and molecular mechanism of SNHG14 in the modulation of NSCLC progression, with the aim of providing a new diagnostic predictor and a valuable therapeutic target for NSCLC.

Methods

Study subjects

A total of 74 paired NSCLC and normal tissue specimens were collected from NSCLC patients. These did not include patients who had received any treatment before surgery. The tissues were scored at $\sim 80^\circ$C for further use. Written informed consents were provided by all participants and the ethics committee of the Affiliated Rizhao People’s Hospital of Jining Medical University approved this study.

Cell culture and cell transfection

Normal human bronchial epithelial 16HBE cells and two NSCLC cell lines (A549 and SK-MES-1) provided by ATCC were cultured in RPMI 1640 medium containing 10% FBS and maintained at 37°C with 5% CO₂ atmosphere.

MiR-206 mimic or inhibitor, SNHG14 siRNA or vector and their corresponding controls were provided by GenePharma (Shanghai, China). They were delivered to A549 and SK-MES-1 cells with the aid of Lipofectamine 2000 reagent (Invitrogen). After transfection for 48 hours, the cells were collected for further analysis.

RT-PCR

TRizol reagent was applied for extracting total RNA from prepared tissues or cells. A NanoDrop 2000 spectrophotometer (Thermo, MA, USA) was used for measuring the RNA concentration and quality. PrimeScript RT reagent Kit (TaKaRa) and OneStep PrimeScript miRNA cDNA Synthesis Kit (Qiagen, CA, USA) were used to perform reverse transcription in lncRNA and miRNA quantification, respectively. SYBR Premix Ex Taq II kit (Takara) was used to determine qPCR analysis. GAPDH and U6 were applied for normalization of lncRNA and miRNA, respectively. The expression of tested genes was calculated by $2^{-\Delta\Delta C_{\text{T}}}$ method. The primers sequences used are listed in Table 1.

Western blot

RIPA buffer containing protease inhibitors was applied for preparing cell lysates. After proteins were separated by

![Figure 1](image.png)

**Table 1** Primer sequences for RT-qPCR

| Primer   | Sequence                  |
|----------|---------------------------|
| SNHG14   | 5'-GGGTGTTTACGTAGACCAGAACC-3' |
|          | 5'-CTTCAAAAGCCTTCTGCTTAG-3'  |
| miR-206  | 5'-CCAAGCGGAGTCCTGAC-3'     |
|          | 5'-GCCTACATGTTGCTAGCTC-3'    |
| U6       | 5'-GCTTCGGAGCTATACCTACAAAT-3'|
|          | 5'-CGCTTACGAATTGTGTCAT-3'    |
| G6PD     | 5'-TGCTTCCATAGCCGATGATAC-3'  |
|          | 5'-TGGTGCTGCTTGTCAT-3'       |
| GAPDH    | 5'-CCAAAAATCAGATGGGGCAATGGTG-3' |
|          | 5'-TGATGGCAGACTGCTGAC-3'     |

G6PD, Glucose-6-phosphate dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; U6, small nuclear RNA, snRNA.
SDS-PAGE, followed by transfer to NC membranes, they were incubated with nonfat milk for 1 hour. Primary antibodies were subsequently incubated overnight at 4°C and then secondary antibodies for 1 hour. The primary antibodies used in this study were anti-G6PD antibody and anti-GAPDH antibody.

**CCK-8 assay**

A CCK-8 Kit was used to assay the altered cell viability after different transfections. After transfection with miR-206 mimic, SNHG14 siRNA or vector and their corresponding controls, NSCLC cells were seeded into 48-well plates and cultured for one, two, three, and four days. The cells were then treated with CCK-8 solution for another 2 hours. Finally, a spectrophotometer (Thermo, MA, USA) was applied to measure the optical density at 450 nm.

**Transwell assays**

Transwell chambers precoated with or without Matrigel were used to detect cell invasion and migration. Two NSCLC cell lines with different transfections after transfection with miR-206 mimic, SNHG14 siRNA or vector and their corresponding controls, were added inside the chamber. Next, DMEM medium containing 10% FBS was seeded into a 24-well plate and placed into the

---

**Figure 2** SNHG14 modulated NSCLC progression. (a) Measurement of SNHG14 expression in two NSCLC cells after overexpression or silencing SNHG14. NC siRNA, SNHG14 siRNA, NC vector and SNHG14 vector. (b) Cell viability. A549 (▲) SNHG14 vector, (▲) NC vector, (▼) SNHG14 siRNA and (▼) NC siRNA. (c) Cell viability. SK-MES-1 (▲) SNHG14 vector, (▲) NC vector, (▼) SNHG14 siRNA and (▼) NC siRNA. (d) Cell migration. NC siRNA, SNHG14 siRNA, NC vector and SNHG14 vector. (e) Cell invasion. NC siRNA, SNHG14 siRNA, NC vector and SNHG14 vector. *P < 0.05, **P < 0.01.
transwell chamber. After incubation for 24 hours, the invaded or migrated cells was fixed, stained and counted.

**Luciferase reporter assay**

The amplified wild- or mutant type of SNHG14 3’UTR (SNHG14 3’UTR-WT, -MUT) was cloned into the pGL3-reporter vector. With the aid of Lipofectamine 2000 reagent, miR-206 mimic or inhibitor and SNHG14-WT or -MUT were cotransfected into A549 cells. At 48 hours post-transfection, luciferase activity was detected.

**Statistical analysis**

The values were analyzed by SPSS 22.0 software and presented as mean ± SD. P-value significance between the two groups was compared with a Student’s t-test. Tukey’s post hoc test was applied for comparing the significance between multiple groups. P < 0.05 was considered as statistically significant.

**Results**

**SNHG14 was increased in NSCLC**

To detect the role of IncRNA SNHG14’ in NSCLC development, the expression level of SNHG14 was first measured in NSCLC tissues and cells. As a result, the expression level of SNHG14 was dramatically increased in NSCLC tissues compared with nontumor tissues (Fig 1a). Moreover, similar results were found in NSCLC cells. In NSCLC cells, SNHG14 expression was higher relative to that in normal

---

*Thoracic Cancer* 11 (2020) 1202–1210 © 2020 The Authors. *Thoracic Cancer* published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd

---

Figure 3 SNHG14 acted as a sponge for miR-206 in NSCLC cells. (a) The prediction binding sites of SNHG14 and miR-206 are shown. (b, c) The luciferase activity detected in A549 and SK-MES-1 cells with a different transfection of miR-206 mimic, miR-206 inhibitor, con mimic, con inhibitor. con mimic, (■) miR-206 mimic, (□) con inhibitor and (●) miR-206 inhibitor. con mimic, (●) miR-206 mimic, (□) con inhibitor and (●) miR-206 inhibitor. (d) The expression level of miR-206 measured in NSCLC tissues. (e) The mRNA level of miR-206 tested in the two NSCLC cells with different transfections of NC siRNA, SNHG14 siRNA, NC vector and SNHG14 vector. NC siRNA, (●) SNHG14 siRNA, (□) NC vector and (●) SNHG14 vector. *P < 0.05, **P < 0.01.
cells (Fig 1b). These data suggested that high expression of SNHG14 might play a critical role in NSCLC development.

**SNHG14 modulated NSCLC progression**

Next, we examined the effect of SNHG14 on NSCLC progression. Two cancer cells were transfected with SNHG14 siRNA or vector to knockdown or overexpress SNHG14. As show2a, the high knockdown or overexpression efficiency was determined by RT-PCR. CCK-8 assay results showed that decreasing SNHG14 repressed cells, whereas increasing SNHG14 promoted the viability of NSCLC cells (Fig 2b,c). In addition, the findings of transwell migration assay revealed that silencing SNHG14 suppressed cells, while upregulation SNHG14 enhanced the number of migrated cells in both NSCLC cells (Fig 2d). Moreover, the number of invaded cells was also hindered by SNHG14 siRNA, whereas it was facilitated by SNHG14 vector (Fig 2e). These findings indicated that SNHG14 contributes to NSCLC progression.

**SNHG14 acts as a sponge for miR-206 in NSCLC cells**

By using the bioinformatic tool starBase, miR-206 was predicted as the target of SNHG14 (Fig 3a). Dual luciferase reporter assay was then performed to validate the direct binding between miR-206 and SNHG14. As show3b,c, the luciferase activity of SNHG14-WT was decreased in the A549 and SK-MES-1 cells treated with miR-206 mimic in comparison with the control, whereas it increased when treated with miR-206 inhibitor. However, the luciferase activity of SNHG14-MUT showed no change when treated with transfection of miR-206 mimic, miR-206 inhibitor, con mimic, con inhibitor. We then tested miR-206 expression in NSCLC tissues. As shown in Fig 3d, it was decreased in NSCLC tissues relative to normal control. Because its expression was opposite to SNHG14 expression, we investigated whether miR-206 was modulated by SNHG14. The findings revealed that re-expression of SNHG14 were inhibited, while knock-down of SNHG14 facilitated miR-206 mRNA expression (Fig 3e). These data showed that miR-206 was the target of SNHG14 in NSCLC.
SNHG14 regulated NSCLC development by targeting miR-206

Next, we explored miR-206 effect on SNHG14 in modulating NSCLC development. Two cancer cells were treated with SNHG14 siRNA or vector, combined with miR-206 mimic. The cell viability was decreased in the SNHG14 siRNA group compared with the control group, and significantly decreased in the SNHG14 siRNA+miR-206 mimic group in comparison with the SNHG14 siRNA group (Fig 4a). However, the cell viability was increased by the SNHG14 vector, while inhibited by the miR-206 mimic (Fig 4b). Moreover, transwell migration assay results showed that the miR-206 mimic further promoted the inhibitory effect of SNHG14 siRNA on cell migration (Fig 4c), and overturned the promoting effect of SNHG14 vector on cell migration (Fig 4d). More importantly, similar trends of cell invasion and cell migration were observed in Fig 4e,f. In summary, these findings demonstrated that SNHG14 modulated NSCLC progression by targeting miR-206.

G6PD was the target of miR-206

TargetScan was applied for predicting the potential targets of miR-206 and G6PD was identified as the possible target (Fig 5a). To further verify the predicted target relationship, dual luciferase reporter assay was applied. As seen in Fig 5b,c, miR-206 mimic significantly reduced the luciferase activity of G6PD 3’UTR-WT, but not G6PD 3’UTR-Mut. Moreover, we detected G6PD expression was affected by miR-206. Results showed that the mRNA and

![Figure 5](image_url)

Figure 5 G6PD served as the target of miR-101 in NSCLC cells. (a) MiR-206 and G6PD are the binding sites. (b, c) The luciferase activity of G6PD 3’UTR-WT or -MUT in A549 and SK-MES-1 cells after being treated with different transfections of miR-206 mimic, miR-206 inhibitor, con mimic, con inhibitor. A549 ( ) con mimic, ( ) miR-206 mimic, ( ) con inhibitor and ( ) miR-206 inhibitor. SK-MES-1 ( ) con mimic, ( ) miR-206 mimic, ( ) con inhibitor and ( ) miR-206 inhibitor. (d, e) The protein level and mRNA level of G6PD tested in the two NSCLC cells with different transfections. ( ) con mimic, ( ) miR-206 mimic, ( ) con inhibitor and ( ) miR-206 inhibitor. *P < 0.05, **P < 0.01.
protein level of G6PD was significantly decreased by over-expression of miR-206, while increased by inhibiting miR-206 (Fig 5d,e). These findings suggested that G6PD served as miR-206' direct target.

G6PD served as a downstream target of SNHG14 in NSCLC cells

We then explored whether G6PD was modulated by SNHG14 via miR-206. As show6a, SNHG14 upregulation facilitated G6PD mRNA and protein expression and was then repressed when combined with the miR-206 mimic. However, knockdown of SNHG14 suppressed G6PD expression, while simultaneously with overexpression of miR-206 further inhibited G6PD expression (Fig 6b). In addition, in NSCLC tissues, the relationship between G6PD expression and SNHG14 expression was positive (Fig 6c), but the correlation of G6PD with miR-206 expression was negative (Fig 6d). This confirms that SNHG14 enhanced G6PD expression via hindering miR-206 expression in NSCLC.

Figure 6  G6PD served as the downstream target of SNHG14 in NSCLC. (a) G6PD mRNA. [Control, □ SNHG14 vector and □ SNHG14 vector+miR-206 mimic. (b) G6PD protein level detected in the two NSCLC cells with different transfections of SNHG14 vector and miR-206 mimic. □ Control, □ SNHG14 siRNA and □ SNHG14 siRNA+miR-206 mimic. (c) The relationship between G6PD and SNHG14 expression. (d) The relationship between G6PD and miR-206 expression. *P < 0.05, **P < 0.01.
Discussion

In the present study, we showed that SNHG14 was highly expressed in NSCLC tissues and cells. Overexpression of SNHG14 contributed to cell proliferation, invasion and migration. However, knockdown of SNHG14 inhibited NSCLC progression. More importantly, miR-206 was verified as the downstream effector of SNHG14 and G6PD was the direct target of miR-206. Moreover, we proved that SNHG14 could facilitate G6PD expression by impeding miR-206. Collectively, we demonstrated that SNHG14 contributed to NSCLC progression by regulating miR-206/G6PD axis.

There is increasing evidence that lncRNAs are related to the development of various tumors. Previous studies have showed that lncRNA SNHG14 promoted clear cell renal cell carcinoma migration and invasion as an oncogene. Also, Liu et al. revealed that SNHG14 facilitated the development of gastric cancer. Dong et al. showed that SNHG14 promotes trastuzumab chemoresistance in breast cancer. Similar results were found in our study. We reported that lncRNA SNHG14 was highly expressed in NSCLC tissues. Overexpression lncRNA SNHG14 facilitated, while silence lncRNA SNHG14 inhibited NSCLC proliferation, invasion and migration.Briefly, lncRNA SNHG14 revealed the promotion effect on the development of NSCLC.

LncRNAs have been reported to sponge miRNAs to modulate the derepression of miRNA targets, consequently regulating the progress of different diseases. For example, Li and colleagues showed that SNHG14 acted as sponge for miR-219 and miR-125 in facilitating ovarian cancer viability and metastasis. Xie et al. found that miR-193a served as the target of SNHG14 in promoting breast cancer cell proliferation and invasion. More importantly, SNHG14 conferred the gefitinib resistance via miR-206/ABCB1 axis in NSCLC. Here, for the first time we showed that SNHG14 served as a sponge for miR-206 in promoting lung cancer cell viability, invasion and migration.

As already determined, miRNAs regulate tumors development by targeting their mRNAs through binding to 3’UTR. In lung cancer, miR-206 is reported to target several mRNA genes. For instance, MET function as the target of miR-206 in suppressing lung cancer progression. Moreover, Ren et al. showed that miR-206 showed suppression effect on colorectal cancer via targeting FMNL2. Zhang et al. reported that SOX9 took part in NSCLC progression as the target of miR-206. In this study, we determined G6PD as the target of miR-206 in NSCLC. Specifically, we proved that SNHG14 positively regulated G6PD expression by sponging miR-206 in NSCLC.

In summary, we conclude that SNHG14 plays a role in NSCLC. The promotion role of SNHG14 in NSCLC progression could be inhibited by miR-206. SNHG14 enhanced G6PD expression by suppressing miR-206. Our results provide evidence that SNHG14/miR-206/G6PD axis regulated the development of NSCLC. Therefore, SNHG14 might serve as a promising therapeutic target for NSCLC.

Acknowledgments

This study was supported by the Support Project for Young Teachers of Jining Medical University (JY2016KJ053Y); Shandong Medical and Health Science and Technology Development Plan Project (2017WS717).

Disclosure

No authors report any conflict of interest.

References

1. Chen Z, Li JL, Lin S et al. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest 2016; 126: 2267–79.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics. CA Cancer J Clin 2014; 64: 9–29.
3. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer 2014; 14: 535–46.
4. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 479–85.
5. Arab K, Park YJ, Lindroth AM et al. Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A. Mol Cell 2014; 55: 604–14.
6. Doubeni CA, Gabler NB, Wheeler CM et al. Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium. CA Cancer J Clin 2018; 68: 199–216.
7. Gu J, Wang Y, Wang X et al. Downregulation of IncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer. Cancer Lett 2018; 434: 1–10.
8. Lin C, Yang L. Long noncoding RNA: Wiring signaling circuitry. Trends Cell Biol 2018; 28: 287–301.
9. Lan T, Yuan K, Yan X et al. IncRNA SNHG10 facilitates hepatocarcinogenesis and metastasis by modulating its homolog SCARNA13 via a positive feedback loop. Cancer Res 2019; 79 (13): 3220–34.
10. Wang M, Mao C, Ouyang L et al. Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ 2019; 26: 2329–43.
11. Shi X, Liu Z, Liu Z et al. Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and...
suppressing LATS2 in non-small-cell lung cancer. *EBioMedicine* 2018; 37: 177–87.

12 Yu DJ, Li YH, Zhong M. LncRNA FBXL19-AS1 promotes proliferation and metastasis via regulating epithelial-mesenchymal transition in non-small cell lung cancer. *Eur Rev Med Pharmacol Sci* 2019; 23: 4800–6.

13 Zheng FX, Wang XQ, Zheng WX, Zhao J. Long noncoding RNA HOXA-AS2 promotes cell migration and invasion via upregulating IGF-2 in non-small cell lung cancer as an oncogene. *Eur Rev Med Pharmacol Sci* 2019; 23: 4793–9.

14 Chen T, Qin S, Gu Y, Pan H, Bian D. Long non-coding RNA NORAD promotes the occurrence and development of non-small cell lung cancer by adsorbing MiR-656-3p. *Mol Genet Genomic Med* 2019; 7: e757.

15 Li J, Wang AS, Wang S et al. LncSNHG14 promotes the development and progression of bladder cancer by targeting miRNA-150-5p. *Eur Rev Med Pharmacol Sci* 2019; 23: 1022–9.

16 Li L, Zhang R, Li SJ. Long noncoding RNA SNHG14 promotes ovarian cancer cell proliferation and metastasis via sponging miR-219a-5p. *Eur Rev Med Pharmacol Sci* 2019; 23: 4136–42.

17 Zhang YY, Li M, Xu YD, Shang J. LncRNA SNHG14 promotes the development of cervical cancer and predicts poor prognosis. *Eur Rev Med Pharmacol Sci* 2019; 23: 3664–71.

18 Ji N, Wang Y, Bao G, Yan J, Ji S. LncRNA SNHG14 promotes the progression of cervical cancer by regulating miR-206/YWHAZ. *Pathol Res Pract* 2019; 215: 668–75.

19 Cui J, Pan Y, Wang J, Liu Y, Wang H, Li H. MicroRNA-206 suppresses proliferation and predicts poor prognosis of HR-HPV-positive cervical cancer cells by targeting G6PD. *Oncol Lett* 2018; 16: 5946–52.

20 Liu G, Ye Z, Zhao X, Ji Z. SP1-induced up-regulation of LncRNA SNHG14 as a ceRNA promotes migration and invasion of clear cell renal cell carcinoma by regulating NWASP. *Am J Cancer Res* 2017; 7: 2515–25.

21 Liu Z, Yan Y, Cao S, Chen Y. Long non-coding RNA SNHG14 contributes to gastric cancer development through targeting miR-145/SOX9 axis. *J Cell Biochem* 2018; 119: 6905–13.

22 Dong H, Wang W, Chen R et al. Exosome-mediated transfer of lncRNAsNHSHG14 promotes trastuzumab chemoresistance in breast cancer. *Int J Onco* 2018; 53: 1013–26.

23 Song YX, Sun JX, Zhao JH et al. Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion. *Nat Commun* 2017; 8: 289.

24 Zhao YL, Huang YM. LncSNHG14 promotes ovarian cancer by targeting microRNA-125a-5p. *Eur Rev Med Pharmacol Sci* 2019; 23: 3235–42.

25 Xie SD, Qin C, Jin LD et al. Long noncoding RNA SNHG14 promotes breast cancer cell proliferation and invasion via sponging miR-193a-3p. *Eur Rev Med Pharmacol Sci* 2019; 23: 2461–8.

26 Wu K, Li J, Qi Y et al. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p. *Biomed Pharmacother* 2019; 116: 108995.

27 Chen X, Tong ZK, Zhou JY, Yao YK, Zhang SM, Zhou JY. MicroRNA-206 inhibits the viability and migration of human lung adenocarcinoma cells partly by targeting MET. *Oncol Lett* 2016; 12: 1171–7.

28 Ren XL, He GY, Li XM et al. MicroRNA-206 functions as a tumor suppressor in colorectal cancer by targeting FMNL2. *J Cancer Res Clin Oncol* 2016; 142: 581–92.

29 Zhang YJ, Xu F, Zhang YJ, Li HB, Han JC, Li L. miR-206 inhibits non small cell lung cancer cell proliferation and invasion by targeting SOX9. *Int J Clin Exp Med* 2015; 8: 9107–13.